Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials

Fulvestrant (‘Faslodex’) is a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects. Early efficacy data from phase I/II trials have demonstrated fulvestrant to be effective and well tolerated. Two randomised phase III trials hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergote, I, Robertson, J F R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750769/
https://www.ncbi.nlm.nih.gov/pubmed/15094759
http://dx.doi.org/10.1038/sj.bjc.6601631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750769/
https://www.ncbi.nlm.nih.gov/pubmed/15094759
http://dx.doi.org/10.1038/sj.bjc.6601631

Ejemplares similares